Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

Trial Details

NCT ID

NCT05681780

Phase

PHASE1

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Tumor-infiltrating Lymphocytes (TIL)
Nivolumab
Cyclophosphamide
Fludarabine
Tumor-infiltrating Lymphocyte Therapy
Interleukin-2 (IL2)

Locations (sample)

Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

Age greater than or equal to 18 years
Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with an activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB…
ECOG performance status of 0 or 1
Expected survival ≥ 4 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →